Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Short term Debt: 2016-2023

Historic Short term Debt for Cartesian Therapeutics (RNAC) over the last 5 years, with Dec 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Short term Debt rose 233.97% to $28.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $28.3 million, marking a year-over-year increase of 233.97%. This contributed to the annual value of $28.3 million for FY2023, which is 233.97% up from last year.
  • Cartesian Therapeutics' Short term Debt amounted to $28.3 million in Q4 2023, which was up 176.57% from $10.2 million recorded in Q2 2023.
  • Over the past 5 years, Cartesian Therapeutics' Short term Debt peaked at $28.3 million during Q4 2023, and registered a low of $460,000 during Q1 2021.
  • Its 3-year average for Short term Debt is $7.3 million, with a median of $5.9 million in 2022.
  • In the last 5 years, Cartesian Therapeutics' Short term Debt tumbled by 97.27% in 2021 and then skyrocketed by 1,368.10% in 2023.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Short term Debt stood at $18.9 million in 2019, then tumbled by 61.09% to $8.4 million in 2020, then tumbled by 72.67% to $6.0 million in 2021, then soared by 42.19% to $8.5 million in 2022, then skyrocketed by 233.97% to $28.3 million in 2023.
  • Its last three reported values are $28.3 million in Q4 2023, $10.2 million for Q2 2023, and $10.2 million during Q1 2023.